ZyVersa Therapeutics Inc
ZVSA
Company Profile
Business description
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Contact
2200 North Commerce Parkway
Suite 208
WestonFL33326
USAT: +1 754 231-1688
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
7
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,456.20 | 90.50 | 1.08% |
| CAC 40 | 7,770.48 | 176.61 | 2.33% |
| DAX 40 | 23,086.65 | 589.67 | 2.62% |
| Dow JONES (US) | 41,317.43 | 564.47 | 1.39% |
| FTSE 100 | 8,596.35 | 99.55 | 1.17% |
| HKSE | 22,504.68 | 385.27 | 1.74% |
| NASDAQ | 17,977.73 | 266.99 | 1.51% |
| Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
| NZX 50 Index | 12,340.48 | 12.59 | 0.10% |
| S&P 500 | 5,686.67 | 82.53 | 1.47% |
| S&P/ASX 200 | 8,238.00 | 92.40 | 1.13% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |